14-day Premium Trial Subscription Try For FreeTry Free
$8.76
+0.180 (+2.10%)
At Close: May 01, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $7.97 $10.47 Wednesday, 1st May 2024 ZYME stock ended at $8.76. This is 2.10% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 5.26% from a day low at $8.55 to a day high of $9.00.
90 days $7.97 $13.14
52 weeks $6.02 $13.14

Historical Zymeworks Inc prices

Date Open High Low Close Volume
Feb 20, 2024 $12.09 $12.53 $11.86 $12.04 569 185
Feb 16, 2024 $11.79 $12.13 $11.60 $12.02 313 583
Feb 15, 2024 $11.59 $11.73 $11.48 $11.71 255 238
Feb 14, 2024 $11.40 $11.51 $11.28 $11.41 243 756
Feb 13, 2024 $11.45 $11.60 $11.16 $11.28 367 378
Feb 12, 2024 $11.19 $11.87 $11.01 $11.82 543 749
Feb 09, 2024 $11.54 $11.72 $11.06 $11.15 290 561
Feb 08, 2024 $11.36 $11.63 $11.25 $11.47 311 608
Feb 07, 2024 $11.40 $11.49 $11.21 $11.33 223 012
Feb 06, 2024 $10.87 $11.44 $10.83 $11.44 278 887
Feb 05, 2024 $11.00 $11.05 $10.76 $10.95 255 661
Feb 02, 2024 $10.94 $11.08 $10.75 $11.00 357 727
Feb 01, 2024 $10.88 $11.08 $10.68 $10.98 299 845
Jan 31, 2024 $10.78 $11.17 $10.61 $10.84 393 054
Jan 30, 2024 $10.69 $10.89 $10.51 $10.79 330 675
Jan 29, 2024 $10.40 $10.72 $10.06 $10.69 291 157
Jan 26, 2024 $10.36 $10.57 $10.26 $10.40 265 180
Jan 25, 2024 $10.32 $10.43 $10.10 $10.32 206 126
Jan 24, 2024 $10.35 $10.43 $10.12 $10.20 242 523
Jan 23, 2024 $10.15 $10.33 $10.02 $10.28 238 108
Jan 22, 2024 $9.92 $10.08 $9.81 $10.05 272 227
Jan 19, 2024 $9.91 $9.92 $9.68 $9.88 326 010
Jan 18, 2024 $10.46 $10.50 $9.64 $9.86 492 150
Jan 17, 2024 $10.43 $10.50 $10.28 $10.49 289 579
Jan 16, 2024 $10.76 $10.78 $10.43 $10.54 233 388
Click to get the best stock tips daily for free!

About Zymeworks Inc

Zymeworks Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 ... ZYME Profile

Golden Star

Ticker Date Change Price
HRB Apr 29 1.00% $47.23
LYG Apr 29 0.391% $2.56
ORA Apr 29 1.95% $64.48
ETSY Apr 26 3.43% $67.43
DHT Apr 24 0.98% $11.28
LPLA Apr 19 1.10% $262.59
MLI Apr 19 7.29% $52.28
PFLT Apr 18 1.33% $11.25
DOOR Apr 18 0.94% $131.39
OCSL Apr 17 0.360% $19.43
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT